ALISO VIEJO, Calif., June 5, 2024 /PRNewswire/ --Neuros Medical, Inc., the maker of the Altius® Direct Electrical Nerve Stimulation System designed for patients with chronic post-amputation pain, today announced the appointment of Zach Stassen, Chief Financial Officer (CFO); Kirk Ellis, Vice President of U.S.

加利福尼亚州ALISO VIEJO，2024年6月5日/PRNewswire/--为慢性截肢后疼痛患者设计的Altius®直接电神经刺激系统制造商Neuros Medical，Inc.今天宣布任命首席财务官扎克·斯塔森（Zach Stassen）；美国副总统柯克·埃利斯。

Sales; and Steve Bosrock, Vice President of Marketing..

销售；还有营销副总裁史蒂夫·博斯洛克。。

'I am thrilled to welcome Zach, Kirk, and Steve to the Neuros team and believe their proven track records commercializing disruptive technologies and building successful companies will add significant value to our organization. These experienced teammates join us at a critical time as we expand our commercial team and prepare to launch the Altius® System in the U.S.,' said David Veino, President and CEO of Neuros Medical..

“我很高兴欢迎扎克、柯克和史蒂夫加入Neuros团队，相信他们将颠覆性技术商业化并建立成功公司的良好记录将为我们的组织带来重大价值。Neuros Medical总裁兼首席执行官大卫·维诺（DavidVeino）说：“在我们扩大商业团队并准备在美国推出Altius®系统的关键时刻，这些经验丰富的队友加入了我们。”。。

Messrs. Stassen, Ellis, and Bosrock bring a combined 65 years of experience in medical devices to the Neuros team and have played pivotal leadership roles in numerous successful product launches and in building companies acquired by Baxter, Boston Scientific, Cardinal Health, Hologic, Johnson and Johnson, Medtronic, and Royal Philips. .

Stassen、Ellis和Bosrock先生为Neuros团队带来了65年的医疗设备经验，并在众多成功的产品发布以及被巴克斯特、波士顿科学、红衣主教健康、Hologic、强生、美敦力和皇家飞利浦收购的建筑公司中发挥了关键的领导作用。。

Mr. Stassen brings more than 20 years of finance, operations, and leadership experience to his new role at Neuros Medical.  Most recently, he served as Chief Financial Officer for ViewRay, Inc., a publicly traded company focused on cancer treatment.  Prior to ViewRay, he served as Chief Financial Officer and Chief Operating Officer for Bolder Surgical, an innovative, privately held surgical instrument company that was acquired by Hologic.  Prior to Bolder Surgical, he held various finance and business development roles at Spectranetics before its acquisition by Royal Philips.

斯塔森先生为他在Neuros Medical的新职位带来了20多年的财务、运营和领导经验。最近，他担任ViewRay，Inc.的首席财务官，这是一家专注于癌症治疗的上市公司。在加入ViewRay之前，他曾担任Bolder Surgical的首席财务官和首席运营官，Bolder Surgical是一家创新的私营手术器械公司，被Hologic收购。在Bolder Surgical之前，他曾在Spectranetics担任过各种财务和业务发展角色，然后被皇家飞利浦收购。

Zach holds a Master of Business Administration degree from the Kellogg School of Management at Northwestern University and a bachelor's degree from Drake University..

扎克拥有西北大学凯洛格管理学院的工商管理硕士学位和德雷克大学的学士学位。。

Mr. Ellis brings over 25 years of medical device sales and leadership experience developing top-tier commercial teams within transformational medical technology companies to his new role at Neuros Medical.  Most recently, he served as Vice President of Sales for Apollo Endosurgery, a publicly traded company focused on endobariatric procedures that was acquired by Boston Scientific.  Prior to Apollo, he served as Vice President of Sales for Relievant Medsystems, a privately held company focused on minimally invasive treatment of low back pain, also acquired by Boston Scientific.  Prior to Relievant Medsystems, Kirk held positions of increasing responsibility in sales & sales leadership for Torax Medical (acquired by Johnson & Johnson) and Barrx Medical (acquired by Medtronic).

Ellis先生在Neuros medical担任新职位时，拥有25年以上的医疗器械销售和领导经验，在转型医疗技术公司中发展顶级商业团队。最近，他担任Apollo Endosurgery的销售副总裁，Apollo Endosurgery是一家上市公司，专注于减肥手术，被波士顿科学收购。在阿波罗之前，他曾担任Relievant Medsystems的销售副总裁，Relievant Medsystems是一家专注于腰痛微创治疗的私营公司，也被波士顿科学收购。在Relievant Medsystems之前，柯克在Torax Medical（被强生收购）和Barrx Medical（被美敦力收购）的销售和销售领导层担任越来越重要的职位。

Kirk holds a Bachelor of Science degree from Northeastern University. .

柯克拥有东北大学理学学士学位。。

Mr. Bosrock brings 20 years of medical device leadership experience building and leading successful commercial teams and launching disruptive products to his new role at Neuros Medical.  He was most recently the Vice President of Marketing and Medical Education for Apollo Endosurgery through the acquisition by Boston Scientific in 2023.  Prior to Apollo, he held various commercial leadership roles with small privately held and publicly traded companies including Torax Medical (acquired by Johnson & Johnson) and Synovis Life Technologies (acquired by Baxter).

博斯洛克先生在Neuros medical担任新职务时，积累了20年的医疗器械领导经验，建立并领导了成功的商业团队，推出了颠覆性产品。在2023年被波士顿科学公司收购后，他最近担任阿波罗内外科市场营销和医学教育副总裁。在阿波罗之前，他曾在小型私营和上市公司担任过各种商业领导职务，包括Torax Medical（被强生收购）和Synovis Life Technologies（被巴克斯特收购）。

Steve holds a Master of Business Administration degree from the Ross School of Business at the University of Michigan and a bachelor's degree from Boston College..

Steve拥有密歇根大学罗斯商学院的工商管理硕士学位和波士顿学院的学士学位。。

About the Altius® Direct Electrical Nerve Stimulation System

关于Altius®直接电神经刺激系统

The Altius® System is a patient-controlled, on demand system that uses Neuros' patented technology to address the underlying cause of post amputation pain by inhibiting pain signal transmission from the damaged peripheral nerves near the site of amputation to the central nervous system.  The system consists of a nerve cuff electrode placed around an affected nerve and an implantable pulse generator (IPG).

Altius®系统是一种患者控制的按需系统，它使用Neuros的专利技术，通过抑制疼痛信号从截肢部位附近受损的周围神经传递到中枢神经系统，来解决截肢后疼痛的根本原因。该系统由放置在受影响神经周围的神经套电极和植入式脉冲发生器（IPG）组成。

Patients initiate an on-demand 30-minute treatment session as needed for targeted pain relief..

患者根据需要启动30分钟的按需治疗，以有针对性地缓解疼痛。。

Caution – Investigational Device. Limited by Federal (or United States) law to investigational use.

注意-研究装置。受联邦（或美国）法律限制用于研究用途。

About Neuros Medical, Inc.

关于Neuros Medical，Inc。

There are over two million amputees in the U.S., with an estimated 185,000 new amputations occurring every year. Post-amputation pain includes both phantom limb pain and residual limb pain and impacts nearly one million Americans, representing a significant unmet medical need as existing treatment options are limited and consist primarily of opioids and gabapentinoids.  Neuros Medical is a privately held company and the maker of the Altius® Direct Electrical Nerve Stimulation System designed for the treatment of chronic post-amputation pain.  Our mission is to reduce pain and restore life for people suffering with post-amputation pain.  We are a passionate team guided by our core values and committed to our patients and the healthcare professionals who care for them..

美国有200多万截肢者，估计每年有185000例新截肢者。截肢后疼痛包括幻肢疼痛和残肢疼痛，影响近100万美国人，由于现有的治疗选择有限，主要由阿片类药物和加巴喷丁类药物组成，因此这是一个严重的未满足的医疗需求。Neuros Medical是一家私营公司，是Altius®直接电神经刺激系统的制造商，该系统旨在治疗慢性截肢后疼痛。我们的使命是减轻截肢后疼痛患者的疼痛并恢复其生命。我们是一支充满激情的团队，以我们的核心价值观为指导，致力于我们的患者和护理他们的医疗保健专业人员。。

Our Core Values: Patients First, Deliver Excellence, Responsible Ambition, Inspire and Empower.

我们的核心价值观：患者至上，追求卓越，负责任的雄心壮志，激励和授权。

For additional information regarding Neuros Medical, please contact:

有关Neuros Medical的更多信息，请联系：

Steve Bosrock, Vice President, Marketing

Steve Bosrock，营销副总裁

sbosrock@neurosmedical.com

sbosrock@neurosmedical.com

www.neurosmedical.com

www.neurosmedical.com

Tel: 440-951-2565

电话：440-951-2565

View original content to download multimedia:https://www.prnewswire.com/news-releases/neuros-medical-strengthens-senior-leadership-team-in-preparation-for-commercialization-of-the-altius-system-302163971.html

查看原始内容以下载多媒体：https://www.prnewswire.com/news-releases/neuros-medical-strengthens-senior-leadership-team-in-preparation-for-commercialization-of-the-altius-system-302163971.html

SOURCE Neuros Medical

来源Neuros Medical